China NMPA Regulatory Strategy CROs
22 published
22 published CROs match China NMPA Regulatory Strategy.
Locations in this set include United States, China, Australia, India, United Kingdom, and Mexico.
Capabilities that show up most often in this set: Biologics (Other), Biologics (Monoclonal Antibodies), Cell Therapy, Gene Therapy, and Small Molecule.
Matching companies
WuXi AppTecGlobal CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries.
uBriGeneuBriGene is a global leader in advanced therapy medicinal products (ATMPs), cell and gene therapy CDMO services, and analytical testing.
Markdown mirror: /services/regulatory-china-nmpa.md